Text Size

Topical cis-urocanic acid prevents ocular surface irritation in both IgE -independent and -mediated rat model

Jauhonen H.-M., Laihia J., Oksala O., Viiri J., Sironen R., Alajuuma P., Kaarniranta K., Leino L.


  • 2017
  • Graefe's Archive for Clinical and Experimental Ophthalmology
View publication
  • Therapeutic Area

    Front of the eye (FOTE)

  • Categories

    Preclinical development

  • Affiliations

    Department of Ophthalmology, Kuopio University Hospital, Kuopio, Finland; Institute of Clinical Medicine, Department of Ophthalmology, University of Eastern Finland, Kuopio, Finland; Department of Ophthalmology, University of Eastern Finland and Kuopio University Hospital, Finland, P.O. Box 1627, Kuopio, FIN-70211, Finland; BioCis Pharma Ltd, Turku, Finland; Santen Oy, Tampere, Finland; Institute of Clinical Medicine, Department of Pathology and Forensic Medicine, University of Eastern Finland, Kuopio, Finland; Department of Pathology, Kuopio University Hospital, Kuopio, Finland

Related Publications

Six-month efficacy and safety of oxymetazoline hydrochloride 0.1% in Japanese patients with acquired blepharoptosis: a phase 3 study

Ishikawa H., Oka K., Inoue H.


Tear Biomarkers of Topical Sirolimus in Meibomian Gland Dysfunction: A Randomized Trial

Zhou L.; Shimizu H.; Togashi Y.; Kirihara T.; Yang Y.; Lam C.T.; Shimada H.; Tong L.


Layer-by-layer tear film measurement in patients with dry eye and meibomian gland dysfunction

Arita R., Takeuchi G., Sasai K., Nakamura M., Akiba M.


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022